Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD urged to overturn decision on flunixin
Flunixin is a common analgesic used in horses with colic

Product suspended over potential risk to humans

Leading equine veterinary association BEVA is urging the Veterinary Medicines Directorate (VMD) to overturn its decision to suspend the sale of flunixin.

Flunixin is a common analgesic used in horses with colic, as well as for those undergoing surgery and other conditions. On Thursday (26 July), the VMD suspended the product after the Committee for Medicinal Products for Veterinary Use (CVMP) said that a solvent in the injectable formulation - diethanolamine - could pose a risk to humans.

Now BEVA is calling on the VMD to overturn this decision in horses not destined for the human food chain, to reduce the potential impact on equine welfare. It argues that the decision had been made without warning or consultation with the veterinary profession.

“BEVA is fully supportive of all attempts to promote food safety, however, flunixin is widely viewed as the gold-standard painkiller in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic,” said BEVA president Jonathan Pycock.

“BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue.

“BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”

Used widely throughout the veterinary industry, flunixin is the only medicine licensed for the treatment of sepsis. BEVA states that no recall notices have been issued and therefore veterinary surgeons may continue to prescribe medicines that are in stock.

A disruption to the supply chain, however, could lead to shortages of this medicine in clinical practic, it said. 

Image (C) Redwings Horse Sanctuary

Become a member or log in to add this story to your CPD history

Update to TB Advice services

News Story 1
 Vets wishing to access TB Advice services can now use a digital contact form, following updates announced by the APHA.

This new, streamlined service allows customers to provide all necessary information upfront, minimising additional contact between the APHA and the customer. It also ensures questions are directed to the right team, significantly reducing response times.

More contact forms are expected to be announced in the coming months. For more information, visit Gov.uk  

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.